TY - JOUR
AU - Huiru Dong
AU - Erin J. Stringfellow
AU - Alton Russell
AU - Mohammad S. Jalali
A1 - 
AD - Massachusetts General Hospital Institute for Technology Assessment, Harvard Medical School, Boston, MA, US msjalali@mgh.harvard.edu; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, PQ, Canada ; Jalali, Mohammad S.,101 Merrimac St, Ste 1010, Room 1032,Boston,US,02114,Massachusetts General Hospital Institute for Technology Assessment,msjalali@mgh.harvard.edu
BT - JAMA Psychiatry
C5 - Opioids & Substance Use ; Healthcare Disparities
CP - 1
DB - APA PsycInfo®
DO - 10.1001/jamapsychiatry.2022.3673
IS - 1
JF - JAMA Psychiatry
LA - English
PY - 2023
SN - 2168-622X, 2168-622X
SP - 93
EP - 95+
ST - Racial and ethnic disparities in buprenorphine treatment duration in the US
T1 - Racial and ethnic disparities in buprenorphine treatment duration in the US
T2 - JAMA Psychiatry
TI - Racial and ethnic disparities in buprenorphine treatment duration in the US
U1 - Opioids & Substance Use ; Healthcare Disparities
U3 - 10.1001/jamapsychiatry.2022.3673
VL - 80
VO - 2168-622X, 2168-622X
Y1 - 2023
ER -